Alkermes’ schizophrenia / bipolar disorder candidate has experts mixed on how October FDA AdCom will assess Phase III weight gain data

The AdCom will likely question whether or not ALKS-3831, a formulation of samidorphan and generically available olanzapine, provided a clinically meaningful reduction in the common weight gain side effect versus olanzapine. Credit: Atelier211 / Shutterstock.



  • Alkermes